Market Cap 1.52B
Revenue (ttm) 0.00
Net Income (ttm) -122.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 704,800
Avg Vol 1,040,702
Day's Range N/A - N/A
Shares Out 57.60M
Stochastic %K 15%
Beta -1.65
Analysts Strong Sell
Price Target $76.00

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
Meltingflame
Meltingflame Oct. 27 at 7:39 PM
$GPCR Wow! Had to check if there was news... None. I like it all the sane. We expect news this qtr.
0 · Reply
fx_lux99
fx_lux99 Oct. 27 at 6:18 PM
0 · Reply
topstockalerts
topstockalerts Oct. 27 at 6:15 PM
$GPCR Is it going higher? Comment below...
0 · Reply
judgeyoung2
judgeyoung2 Oct. 27 at 5:31 PM
$GPCR Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 4:58 PM
$NVO vs. $GPCR — Which obesity play has the edge right now? Novo Nordisk is dealing with headwinds and leadership changes, while Structure Therapeutics is gearing up for key obesity-drug data later this year — a make-or-break moment for investors watching the space. Full comparison and outlook here 👉 https://www.zacks.com/stock/news/2776570/nvo-vs-gpcr-which-obesity-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2776570-teaser-17580&ADID=SYND_STOCKTWITS_TWEET_2_2776570_TEASER_17580
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:58 PM
$NVO vs. $GPCR — Which is the better bet in obesity treatment? 🤔 NVO faces headwinds with competition from Eli Lilly and leadership transitions, while GPCR is gearing up for pivotal study data releases. Despite being a clinical-stage biotech with no marketed products, GPCR carries a Zacks Rank #3 (Hold) compared to NVO’s Zacks Rank #4 (Sell). Opportunity assessment here 👉 https://www.zacks.com/stock/news/2776570/nvo-vs-gpcr-which-obesity-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2776570-body-17559&ADID=SYND_STOCKTWITS_TWEET_2_2776570_BODY_17559
2 · Reply
Quantumup
Quantumup Oct. 23 at 2:30 PM
Cantor has Strong Words on $VKTX's Oral: Viking also mentioned on the call that a manuscript for the Phase 2 VENTURE study was accepted for publication in a leading medical journal and should be published in early-2026. $GPCR $LLY $NVO $AMGN PFE MRK 👀Positive and Strong Words from Seedhouse on the Oral: VENTURE Phase 2 data publication in leading medical journal: Early-2026 (will discharge any lingering questions about strength of data compared to tirzepatide and others).😱
0 · Reply
Quantumup
Quantumup Oct. 23 at 12:02 PM
Wow, Seedhouse/Cantor just called the $VKTX (Overweight; $105 PT) 3Q update transformative and said that "this was the most bullish update Viking has given since we started covering the stock more than 7 years ago." $GPCR $LLY $NVO $AMGN PFE MRK Cantor additionally said: VKTX just crystallized five critically important data catalysts in the next 24 months, and Viking affirmed cash on hand of >$700M was sufficient to get through all of them.
0 · Reply
biolover
biolover Oct. 23 at 10:20 AM
$AMGN $GPCR $LLY $NVO $VKTX Someone finally reaching this conclusion about $VKTX oral phase 3 size “We also believe the oral Phase 3 program could enroll fewer patients than subcutaneous by leveraging the ~5,500 patient safety databases from the VANQUISH studies.”
1 · Reply
Quantumup
Quantumup Oct. 23 at 10:14 AM
BTIG reiterated $VKTX Buy/$125 $GPCR $LLY $NVO $AMGN PFE MRK BTIG said in its note:
1 · Reply
Latest News on GPCR
Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 7 months ago

Structure Therapeutics CEO on latest GLP-1 developments


Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 7 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER


Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 11 months ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO


Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs


Structure Therapeutics stock plunges on new GLP-1 drug data

Dec 18, 2023, 8:04 AM EST - 2 years ago

Structure Therapeutics stock plunges on new GLP-1 drug data


Final Trades: Rivian, Pfizer, Treasury Bonds and more

Sep 29, 2023, 6:26 PM EDT - 2 years ago

Final Trades: Rivian, Pfizer, Treasury Bonds and more

PFE RIVN TLT


Meltingflame
Meltingflame Oct. 27 at 7:39 PM
$GPCR Wow! Had to check if there was news... None. I like it all the sane. We expect news this qtr.
0 · Reply
fx_lux99
fx_lux99 Oct. 27 at 6:18 PM
0 · Reply
topstockalerts
topstockalerts Oct. 27 at 6:15 PM
$GPCR Is it going higher? Comment below...
0 · Reply
judgeyoung2
judgeyoung2 Oct. 27 at 5:31 PM
$GPCR Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 4:58 PM
$NVO vs. $GPCR — Which obesity play has the edge right now? Novo Nordisk is dealing with headwinds and leadership changes, while Structure Therapeutics is gearing up for key obesity-drug data later this year — a make-or-break moment for investors watching the space. Full comparison and outlook here 👉 https://www.zacks.com/stock/news/2776570/nvo-vs-gpcr-which-obesity-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2776570-teaser-17580&ADID=SYND_STOCKTWITS_TWEET_2_2776570_TEASER_17580
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:58 PM
$NVO vs. $GPCR — Which is the better bet in obesity treatment? 🤔 NVO faces headwinds with competition from Eli Lilly and leadership transitions, while GPCR is gearing up for pivotal study data releases. Despite being a clinical-stage biotech with no marketed products, GPCR carries a Zacks Rank #3 (Hold) compared to NVO’s Zacks Rank #4 (Sell). Opportunity assessment here 👉 https://www.zacks.com/stock/news/2776570/nvo-vs-gpcr-which-obesity-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2776570-body-17559&ADID=SYND_STOCKTWITS_TWEET_2_2776570_BODY_17559
2 · Reply
Quantumup
Quantumup Oct. 23 at 2:30 PM
Cantor has Strong Words on $VKTX's Oral: Viking also mentioned on the call that a manuscript for the Phase 2 VENTURE study was accepted for publication in a leading medical journal and should be published in early-2026. $GPCR $LLY $NVO $AMGN PFE MRK 👀Positive and Strong Words from Seedhouse on the Oral: VENTURE Phase 2 data publication in leading medical journal: Early-2026 (will discharge any lingering questions about strength of data compared to tirzepatide and others).😱
0 · Reply
Quantumup
Quantumup Oct. 23 at 12:02 PM
Wow, Seedhouse/Cantor just called the $VKTX (Overweight; $105 PT) 3Q update transformative and said that "this was the most bullish update Viking has given since we started covering the stock more than 7 years ago." $GPCR $LLY $NVO $AMGN PFE MRK Cantor additionally said: VKTX just crystallized five critically important data catalysts in the next 24 months, and Viking affirmed cash on hand of >$700M was sufficient to get through all of them.
0 · Reply
biolover
biolover Oct. 23 at 10:20 AM
$AMGN $GPCR $LLY $NVO $VKTX Someone finally reaching this conclusion about $VKTX oral phase 3 size “We also believe the oral Phase 3 program could enroll fewer patients than subcutaneous by leveraging the ~5,500 patient safety databases from the VANQUISH studies.”
1 · Reply
Quantumup
Quantumup Oct. 23 at 10:14 AM
BTIG reiterated $VKTX Buy/$125 $GPCR $LLY $NVO $AMGN PFE MRK BTIG said in its note:
1 · Reply
Quantumup
Quantumup Oct. 22 at 10:45 AM
Oppenheimer⬇️ $TERN's PT to $17 from $20 and reiterated at Outperform after removing TERN-601 from its model—Reminds Investors that Its Investment Thesis has Always Focused on TERN-701 in CML. $VKTX $GPCR $LLY $NVO Oppenheimer said: Following 12 weeks of treatment, TERN-601 showed an up to 4.6% placebo-adjusted weight loss, which was accompanied by a relatively high AE-related discontinuation rate of ~12% across all treatment cohorts. Additionally, three participants had Grade 3 liver enzyme elevations during the follow-up period post-treatment. As a result, it is not surprising that the company will not advance TERN-601. As a reminder, our investment thesis on TERN has always focused on TERN-701 in CML. The TERN-601 termination helps refocus investor attention on TERN-701, as we view the upcoming Ph1 CARDINAL readout in 4Q25 as a key catalyst. We removed TERN-601 from our model driving our new $17 PT (vs. prior $20).
1 · Reply
Quantumup
Quantumup Oct. 15 at 12:08 PM
Truist y'day after the close🏁 $TERN Buy/$20 $NVS $VKTX $GPCR $LLY NVO Truist said in its TERN initiation: Key investment points - 1) Potential best-in-class lead asset w/ promising Ph1 / preclinical data in rare blood cancer, a near ~$1B opportunity; 2) 2nd asset oral GLP-1 agonist derisked by approved drugs; potential to be safe oral option in obesity; 3) Partnerable assets supported by early stage data in multibillion metabolic opportunity like MASH and obesity; 4) Reprioritization to oncology reflects more focused and strategically feasible pivot, in our view; 5) Unadj 2036 peak market opportunity for lead asset $1.X.7B+/~$900M in peak adj revenues to TERN, not reflected at current levels, in our view.
0 · Reply
Meltingflame
Meltingflame Oct. 13 at 7:37 PM
$GPCR News is due this quarter. Patiently waiting. If all goes well, easy double from here.
1 · Reply
twincam
twincam Oct. 11 at 9:35 PM
$GPCR GPCR (Structure Therapeutics) buyout scenario: • 🧪 Asset value: GPCR develops an oral GLP-1, a highly strategic obesity/diabetes drug class. • 📅 Catalyst: ACCESS topline data expected Q4 2025. • 🧠 Potential acquirers: AstraZeneca, Sanofi, and Merck & Co. are the most likely. Pfizer is less likely after its Metsera acquisition. • 📈 Valuation range: • Pre-data fair takeout: $39–50/share (30–60% premium) • Post-strong data fair takeout: $55–65+/share (up to 120% premium possible) • 🏁 Why high interest: Few oral GLP-1 targets remain, strong strategic fit for companies without a GLP-1 franchise. 👉 Bottom line: GPCR is well-positioned as a prime M&A target heading into 2025–2026, especially post-data.
1 · Reply
twincam
twincam Oct. 11 at 9:30 PM
$GPCR GPCR walking quiet while the giants circle the pond 🐊 ACCESS topline Q4 ‘25. Oral GLP-1 could be the real bait. Watch the usual suspects: $AZN, $SNY, $MRK 👀💊
0 · Reply
SendingTheWolf
SendingTheWolf Oct. 8 at 4:35 PM
$GPCR Blind speculation following $VKTX with no data yet.
1 · Reply
Quantumup
Quantumup Oct. 8 at 12:29 PM
Citizens reiterated $TERN Market Outperform-$20 and said, TERN is positioning its oral GLP-1 as differentiated on safety, based on differentiated PKPD dynamics in the gut. $GPCR $LLY $PFE Citizens JMP went on to say:
0 · Reply
optn_trader
optn_trader Oct. 7 at 11:55 AM
0 · Reply